Los puntos clave no están disponibles para este artículo en este momento.
One in four HCT recipients treated with IV cidofovir developed largely reversible nephrotoxicity. Careful selection of patients and close follow-up of renal function may minimize toxicity.
Stern et al. (Fri,) studied this question.